{"filings":[{"id":2744236,"accession_number":"0001193125-26-385355","cik":1745648,"company_name":"Apnimed, Inc.","ticker":"APMD","form_type":"8-K","filed_at":"2026-09-08T21:10:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apnimed Q2 net income $125.9M on gains; FDA accepts AD109 NDA, PDUFA Feb 28 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $125.9M vs net loss $69.5M year-ago; driven by $85.4M gain on equity-method investment sale and $57.1M deposit liability reversal.","R&D expenses $9.9M, down 38% YoY ($16.0M); G&A $12.7M, up >100% from $5.4M on commercialization prep.","Cash and equivalents $172.8M at June 30, 2026; upsized IPO raised $220.8M gross (13.8M shares at $16.00).","FDA accepted NDA for AD109 (proposed name Oxnimbi) for obstructive sleep apnea; PDUFA target date Feb 28, 2027.","Closed senior secured credit facility up to $150M with HealthCare Royalty Partners; monetized Shionogi-Apnimed interest for $100M upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2023996,"accession_number":"0001193125-26-330509","cik":1745648,"company_name":"Apnimed, Inc.","ticker":"APMD","form_type":"8-K","filed_at":"2026-08-03T20:01:02+00:00","items":["5.03","9.01"],"status":"ready","headline":"Apnimed adopts amended charter and bylaws upon IPO consummation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed ninth amended and restated certificate of incorporation on August 3, 2026, effective with IPO closing.","Authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.","Eliminates all references to previously existing series of preferred stock.","Second amended and restated bylaws establish stockholder meeting procedures and advance notice for proposals and director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}